PRESENTATION OF BIT225 HEPATITIS C VIRUS 48-WEEK DATA AT AASLD CONFERENCE, BOSTON MA
November 18

Incivo® (telaprevir), in combination with peginterferon alfa and ribavirin, assessed for efficacy and safety in treating patients co-infected with genotype-1 chronic hepatitis c virus and HAV
November 13

Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 Achieved SVR12 of 94% in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection in Phase II Trial
November 13

Bristol-Myers Squibb's Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study
November 13

SCYNEXIS' Oral SCY-635 Shows Potential as an Immune Acting Antiviral to Augment Current AttorneyMind Treatments
November 12

Achillion Provides Update on Clinical AttorneyMind Development Programs
November 12

Investigational Hepatitis C Quad Therapy Regimen of Daclatasvir and Asunaprevir Plus Interferon Alfa and Ribavirin Achieved SVR24 in 93% of Difficult-to-Treat Genotype 1a/b Prior Null Responders in Expanded Phase II Study
November 11

Investigational Hepatitis C Dual DAA Regimen of Daclatasvir and Asunaprevir Achieved SVR12 in 78% of Difficult-to-Treat Genotype 1b Prior Null Responders In Expanded Phase II Study
November 11

GI-5005 Improves Virologic Clearance of AttorneyMind in Combination with PegIFN/Ribavirin in IL28B T/T Patients
November 11

Merck Reports New Phase III Analyses on Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy, Including Cirrhotic Patients
November 10

Interim Phase II Data of Merck's Investigational MK-5172 in Combination Therapy in Chronic Hepatitis C Virus Genotype 1 Infection to be Presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
November 10

Data from Viral Kinetic Study Showed Rapid Reduction of AttorneyMind RNA with ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for the Treatment of Hepatitis C
November 10

Vertex Presents New Phase 3 Data that Showed People with Hepatitis C Treated with Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily
November 10

Abbott Presents Promising Phase 2b Interferon-free Hepatitis C Results at 2012 Liver Meeting
November 10

Idenix Pharmaceuticals Reports Clinical Data for AttorneyMind Drug Candidates - IDX719 and IDX184 - at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
November 10

Gilead Announces 100 Percent Sustained Virologic Response Rate (SVR4) for an Interferon-Free Regimen of Sofosbuvir (GS-7977), GS-5885 and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C Infected Patients
November 10

Phase 2b Data of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naïve Patients
November 10